Exhibit 99.1
@coherent | PRESS RELEASE |
Editorial Contact: | For Release: |
Leen Simonet | IMMEDIATE |
(408) 764-4161 | April 29, 2010 |
| No. 1247 |
| | |
Coherent, Inc. Reports Strong Quarterly Results, including Record Bookings and Backlog
SANTA CLARA, CA, April 29, 2010 — Coherent, Inc. (NASDAQ, COHR), a world leader in providing photonics based solutions to the commercial and scientific research markets, today announced financial results for its second fiscal quarter ended April 3, 2010.
FINANCIAL HIGHLIGHTS
| | Three Months Ended | | Six Months Ended | |
| | April 3, | | January 2, | | April 4, | | April 3, | | April 4, | |
| | 2010 | | 2010 | | 2009 | | 2010 | | 2009 | |
GAAP Results | | | | | | | | | | | |
(in millions except per share data) | | | | | | | | | | | |
Bookings | | $ | 164.5 | | $ | 158.4 | | $ | 93.8 | | $ | 322.9 | | $ | 197.2 | |
Net sales | | $ | 149.2 | | $ | 122.8 | | $ | 105.4 | | $ | 272.0 | | $ | 229.8 | |
Net income (loss) | | $ | 8.5 | | $ | 4.2 | | $ | (9.1 | ) | $ | 12.7 | | $ | (23.8 | ) |
Diluted EPS | | $ | 0.34 | | $ | 0.17 | | $ | (0.38 | ) | $ | 0.51 | | $ | (0.98 | ) |
| | | | | | | | | | | |
Non-GAAP Results | | | | | | | | | | | |
(in millions except per share data) | | | | | | | | | | | |
Net income (loss) | | $ | 11.3 | | $ | 5.1 | | $ | 0.3 | | $ | 16.4 | | $ | 9.0 | |
Diluted EPS | | $ | 0.45 | | $ | 0.21 | | $ | 0.01 | | $ | 0.66 | | $ | 0.37 | |
SECOND FISCAL QUARTER DETAILS
For the second fiscal quarter ended April 3, 2010, Coherent announced net sales of $149.2 million and net income, on a U.S. generally accepted accounting principles (GAAP) basis, of $8.5 million ($0.34 per diluted share). These results compare to net sales of $105.4 million and net loss of $9.1 million, or $0.38 per share, for the second quarter of fiscal 2009. Non-GAAP net income for the second quarter of fiscal 2010 was $11.3 million or $0.45 per diluted share and non-GAAP net income for the second quarter of fiscal 2009 was $0.3 million, or $0.01 per diluted share. Please see the reconciliation of GAAP to non-GAAP results included at the end of our release.
Net sales for the first quarter of fiscal 2010 were $122.8 million and net income, on a GAAP basis, was $4.2 million ($0.17 per diluted share). Non-GAAP net income for the first quarter of fiscal 2010 was $5.1 million or $0.21 per diluted share.
Bookings received during the three months ended April 3, 2010 of $164.5 million increased 75.3% from $93.8 million in the same prior year period and increased by 3.9% compared to bookings of $158.4 million in the immediately preceding quarter. The book-to-bill ratio was 1.1, resulting in backlog of $217.2 million at April 3, 2010 compared to a backlog of $202.8 million at January 2, 2010 and a backlog of $145.9 million at April 4, 2009.
As of April 3, 2010, year-to-date sales were $272.0 million and net profit was $12.7 million ($0.51 per diluted share) on a GAAP basis compared to the prior year period sales of $229.8 million and a net loss on a GAAP basis of $23.8 million ($0.98 per share). Bookings received for the six month period ended April 3, 2010 were $322.9 million, compared to $197.2 million in bookings received during the same period a year ago.
Coherent ended the quarter with cash and short term investments of $265.1 million, an increase of $24.5 million from cash and short term investments of $240.6 million at January 2, 2010.
“There were a number of noteworthy achievements within the markets we serve. We experienced additional design wins and significant orders for OLED production. There is continuing improvement in the materials processing space for marking applications that support consumer products. And we are seeing signs that elective laser-based medical procedures are recovering, thereby driving demand for a number of products in our portfolio,” said John Ambroseo, Coherent’s President and Chief Executive Officer. “Our second quarter results reinforce two very important points: the value of our R&D focus to secure design wins, especially during the recent downturn, and the inherent leverage in our new operating model. These factors were directly responsible for record bookings, record backlog and a significant step up in earnings. The combination of our backlog and sustained demand in our commercial markets enables us to increase our full fiscal year outlook for net sales to $590-600 million, which is a 35-38% increase over fiscal 2009,” Ambroseo added.
CONFERENCE CALL REMINDER
The Company will host a conference call today to discuss its financial results at 1:30 P.M. Pacific (4:30 P.M. Eastern). A listen-only broadcast of the conference call can be accessed on the Company’s website at either http://www.coherent.com/Investors/ or http://www.earnings.com. For those who are not available to listen to the live broadcast, the call will be archived for approximately three months on both web sites. A transcript of management’s prepared remarks can be found at http://www.coherent.com/Investors/.
Summarized statement of operations information is as follows (unaudited, in thousands except per share data):
| | Three Months Ended | | Six Months Ended | |
| | April 3, | | January 2, | | April 4, | | April 3, | | April 4, | |
| | 2010 | | 2010 | | 2009 | | 2010 | | 2009 | |
| | | | | | | | | | | |
Net sales | | $ | 149,157 | | $ | 122,815 | | $ | 105,422 | | $ | 271,972 | | $ | 229,810 | |
Cost of sales (A) (B) (E) | | 83,544 | | 71,783 | | 65,815 | | 155,327 | | 139,814 | |
Gross profit | | 65,613 | | 51,032 | | 39,607 | | 116,645 | | 89,996 | |
Operating expenses: | | | | | | | | | | | |
Research & development (A) (B) (E) | | 19,488 | | 15,410 | | 15,610 | | 34,898 | | 30,388 | |
Selling, general & administrative (A) (B) (C) (E) | | 31,164 | | 27,979 | | 27,962 | | 59,143 | | 51,590 | |
Impairment of goodwill(D) | | — | | — | | — | | — | | 19,286 | |
Intangibles amortization | | 1,956 | | 1,961 | | 1,894 | | 3,917 | | 3,837 | |
Total operating expenses | | 52,608 | | 45,350 | | 45,466 | | 97,958 | | 105,101 | |
Income (loss) from operations | | 13,005 | | 5,682 | | (5,859 | ) | 18,687 | | (15,105 | ) |
Other income (expense), net(E) | | 1,492 | | 792 | | (1,600 | ) | 2,284 | | (5,830 | ) |
Income (loss) before income taxes | | 14,497 | | 6,474 | | (7,459 | ) | 20,971 | | (20,935 | ) |
Provision for income taxes(F) | | 6,017 | | 2,295 | | 1,671 | | 8,312 | | 2,874 | |
Net income (loss) | | $ | 8,480 | | $ | 4,179 | | $ | (9,130 | ) | $ | 12,659 | | $ | (23,809 | ) |
| | | | | | | | | | | |
Net income (loss) per share: | | | | | | | | | | | |
Basic | | $ | 0.34 | | $ | 0.17 | | $ | (0.38 | ) | $ | 0.51 | | $ | (0.98 | ) |
Diluted | | $ | 0.34 | | $ | 0.17 | | $ | (0.38 | ) | $ | 0.51 | | $ | (0.98 | ) |
| | | | | | | | | | | |
Shares used in computation: | | | | | | | | | | | |
Basic | | 24,704 | | 24,469 | | 24,258 | | 24,587 | | 24,202 | |
Diluted | | 24,996 | | 24,678 | | 24,258 | | 24,837 | | 24,202 | |
(A) Stock-related compensation expense included in operating results is summarized below (all footnote amounts are unaudited, in thousands):
| | Three Months Ended | | Six Months Ended | |
Stock-related compensation | | April 3, | | January 2, | | April 4, | | April 3, | | April 4, | |
expense | | 2010 | | 2010 | | 2009 | | 2010 | | 2009 | |
Cost of sales | | $ | 256 | | $ | 219 | | $ | 177 | | $ | 475 | | $ | 461 | |
Research & development | | 280 | | 273 | | 239 | | 553 | | 434 | |
Selling, general & administrative | | 1,514 | | 1,670 | | 2,009 | | 3,184 | | 3,220 | |
Impact on income (loss) from operations | | $ | 2,050 | | $ | 2,162 | | $ | 2,425 | | $ | 4,212 | | $ | 4,115 | |
For the quarters ended April 3, 2010, January 2, 2010 and April 4, 2009, the impact on net income (loss), net of tax was $1,873 ($0.07 per diluted share), $1,519 ($0.06 per diluted share) and $1,972 ($0.08 per share), respectively. For the six months ended April 3, 2010 and April 4, 2009, the impact on net income (loss), net of tax was $3,392 ($0.13 per diluted share) and $3,125 ($0.13 per share), respectively.
(B) Restructuring costs included in operating results are summarized below:
| | Three Months Ended | | Six Months Ended | |
| | April 3, | | January 2, | | April 4, | | April 3, | | April 4, | |
Restructuring costs | | 2010 | | 2010 | | 2009 | | 2010 | | 2009 | |
Cost of sales | | $ | 707 | | $ | 309 | | $ | 3,153 | | $ | 1,016 | | $ | 6,175 | |
Research & development | | 168 | | 409 | | 824 | | 577 | | 1,290 | |
Selling, general & administrative | | 685 | | 518 | | 1,023 | | 1,203 | | 1,641 | |
Impact on income (loss) from operations | | $ | 1,560 | | $ | 1,236 | | $ | 5,000 | | $ | 2,796 | | $ | 9,106 | |
For the quarters ended April 3, 2010, January 2, 2010 and April 4, 2009, the impact on net income (loss), net of tax was $978 ($0.04 per diluted share), $813 ($0.03 per diluted share) and $4,463 ($0.18 per share), respectively. For the six months ended April 3, 2010 and April 4, 2009, the impact on net income (loss), net of tax was $1,791 ($0.07 per diluted share) and $7,076 ($0.29 per share), respectively.
(C) The quarter ended January 2, 2010 includes a $2,185 ($1,438 net of tax ($0.06 per diluted share)) net receipt from the settlement of litigation resulting from our internal stock option investigation. The quarter ended April 4, 2009 includes $398 ($356 net of tax ($0.01 per share)) of costs related to litigation resulting from our internal stock option investigation. The six months ended April 3, 2010 includes $2,185 ($1,438 net of tax ($0.06 per diluted share)) net receipt from the settlement of litigation resulting from our internal stock option investigation. The six months ended April 4, 2009 includes $840 ($625 net of tax ($0.03 per share)) of costs related to litigation resulting from our internal stock option investigation.
(D) The six months ended April 4, 2009 include a $19,286 ($0.80 per diluted share) non-cash charge for the impairment of all of the goodwill of our Commercial Lasers and Components segment.
(E) Changes in deferred compensation plan liabilities are included in cost of sales and operating expenses while gains and losses on deferred compensation plan assets are included in other income (expense) net. Deferred compensation expense (benefit) included in operating results is summarized below:
| | Three Months Ended | | Six Months Ended | |
Deferred compensation | | April 3, | | January 2, | | April 4, | | April 3, | | April 4, | |
expense (benefit) | | 2010 | | 2010 | | 2009 | | 2010 | | 2009 | |
Cost of sales | | $ | 4 | | $ | 32 | | $ | (54 | ) | $ | 36 | | $ | (228 | ) |
Research & development | | 30 | | 132 | | (96 | ) | 162 | | (1,084 | ) |
Selling, general & administrative | | 204 | | 1,114 | | (1,001 | ) | 1,318 | | (6,785 | ) |
Impact on income (loss) from operations | | $ | 238 | | $ | 1,278 | | $ | (1,151 | ) | $ | 1,516 | | $ | (8,097 | ) |
For the quarters ended April 3, 2010, January 2, 2010 and April 4, 2009, the impact on other income (expense) net from gains or losses on deferred compensation plan assets was income of $97, income of $1,063 and expense of $1,222, respectively. For the six months ended April 3, 2010 and April 4, 2009, the impact on other income (expense) net was income of $1,160 and expense of $8,020, respectively.
(F) The quarter and six-months ended April 4, 2009 includes a tax charge of $2,666 ($0.11 per share) resulting from a recently enacted change in state tax law.
Summarized balance sheet information is as follows (unaudited, in thousands):
| | April 3,
2010 | | October 3,
2009 | |
ASSETS | | | | | |
Current assets: | | | | | |
Cash, cash equivalents and short-term investments | | $ | 265,109 | | $ | 243,635 | |
Accounts receivable, net | | 84,598 | | 74,235 | |
Inventories | | 99,144 | | 97,767 | |
Prepaid expenses and other assets | | 72,143 | | 67,133 | |
Total current assets | | 520,994 | | 482,770 | |
Property and equipment, net | | 94,972 | | 98,792 | |
Other assets | | 172,863 | | 172,042 | |
Total assets | | $ | 788,829 | | $ | 753,604 | |
| | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | |
Current liabilities: | | | | | |
Current portion of long-term obligations | | $ | 20 | | $ | 9 | |
Accounts payable | | 29,382 | | 21,639 | |
Other current liabilities | | 87,131 | | 64,694 | |
Total current liabilities | | 116,533 | | 86,342 | |
Other long-term liabilities | | 88,064 | | 91,691 | |
Total stockholders’ equity | | 584,232 | | 575,571 | |
Total liabilities and stockholders’ equity | | $ | 788,829 | | $ | 753,604 | |
Reconciliation of GAAP to Non-GAAP net income (unaudited, in thousands, net of tax):
| | Three Months Ended | | Six Months Ended | |
| | April 3,
2010 | | January 2, 2010 | | April 4,
2009 | | April 3,
2010 | | April 4,
2009 | |
GAAP net income (loss) | | $ | 8,480 | | $ | 4,179 | | $ | (9,130 | ) | $ | 12,659 | | $ | (23,809 | ) |
Stock option investigation and litigation expense (benefit) | | — | | (1,438 | ) | 356 | | (1,438 | ) | 625 | |
Stock-related compensation expense | | 1,873 | | 1,519 | | 1,972 | | 3,392 | | 3,125 | |
Impairment of goodwill | | — | | — | | — | | — | | 19,286 | |
Restructuring costs | | 978 | | 813 | | 4,463 | | 1,791 | | 7,076 | |
One-time tax expense | | — | | — | | 2,666 | | — | | 2,666 | |
Non-GAAP net income | | $ | 11,331 | | $ | 5,073 | | $ | 327 | | $ | 16,404 | | $ | 8,969 | |
| | | | | | | | | | | |
Non-GAAP net income per diluted share | | $ | 0.45 | | $ | 0.21 | | $ | 0.01 | | $ | 0.66 | | $ | 0.37 | |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, as defined under the Federal securities laws. These forward-looking statements include the statements in this press release that relate to fiscal 2010 annual net sales guidance, continuing improvement in the materials processing space, and the recovery of elective laser-based medical procedures. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. Factors that could cause actual results to differ materially include risks and uncertainties, including, but not limited to, risks associated with a general market recovery, our successful implementation of our customer design wins, quarterly and annual fluctuations in our net sales and operating results, our and our customers’ exposure to risks associated with worldwide economic slowdowns, the ability of our customers to forecast their own end markets, our ability to increase our sales volumes, our ability to accurately forecast future periods, the impact that our operations and potential acquisitions will have on net sales, customer acceptance and adoption of our new product offerings and continued purchases of our existing products and services, our ability to timely ship our products and our customers’ ability to accept such shipments, our ability to have our customers qualify our product offerings, and other risks identified in the Company’s SEC filings. Readers are encouraged to refer to the risk disclosures described in the Company’s reports on Forms 10-K, 10-Q and 8-K, as applicable and as filed from time-to-time by the Company. Actual results, events and performance may differ materially from those presented herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update these forward-looking statements as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Founded in 1966, Coherent, Inc. is a world leader in providing photonics based solutions to the commercial and scientific research markets and part of the Russell 2000. Please direct any questions to Leen Simonet, Chief Financial Officer at 408-764-4161. For more information about Coherent, visit the Company’s Web site at http://www.coherent.com/ for product and financial updates.
5100 Patrick Henry Dr. . P. O. Box 54980, Santa Clara, California 95056—0980 . Telephone (408) 764-4000
